Goldman Sachs Maintains Neutral on AbbVie, Raises Price Target to $294
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice TargetHot
Goldman Sachs analyst Asad Haider maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $258 to $294.
Goldman Sachs analyst Asad Haider maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $258 to $294.